Effect of an extended KDIGO bundle versus standard of care therapy on persistent acute kidney injury in high-risk patients after major surgery

Beteiligte Wissenschaftler*innen:
Dr. rer. nat. Dipl.-Math. C Szardenings
Akad. Oberrat Dr. Dipl.-Stat. J. Gerß
MSc. K. Fischhuber 

Studienleitung:
Univ.-Prof. Dr. med. A. Zarbock

Förderzeitraum:
2023 - 2025

Study protocol:https://bmjopen.bmj.com/content/15/5/e097333.long

The PrevProgAKI trial investigates whether an extended therapeutic strategy can prevent the transition from moderate or severe acute kidney injury (AKI) to persistent AKI or death in high-risk surgical patients. It is a prospective, single-centre, randomised controlled trial that aims to enrol 480 patients. Among others patient centric composite endpoints, persistence of AKI/death and MAKE90, will be evaluated stratified by patients' CCL14-status using appropriate non-parametric methods like the Cochran-Mantel-Haenzel test or Farrington-Manning score test.